BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 29704233)

  • 1. The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology.
    Macerola E; Rago T; Proietti A; Basolo F; Vitti P
    J Endocrinol Invest; 2019 Feb; 42(2):157-166. PubMed ID: 29704233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytological features and nuclear scores: Diagnostic tools in preoperative fine needle aspiration of indeterminate thyroid nodules with RAS or BRAF K601E mutations?
    Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
    Cytopathology; 2021 Jan; 32(1):37-44. PubMed ID: 32803788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy.
    Decaussin-Petrucci M; Descotes F; Depaepe L; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Lopez J
    Cytopathology; 2017 Dec; 28(6):482-487. PubMed ID: 29094776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
    An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
    Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology.
    Johnson SJ; Hardy SA; Roberts C; Bourn D; Mallick U; Perros P
    Cytopathology; 2014 Jun; 25(3):146-54. PubMed ID: 24417615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates.
    Marchetti I; Lessi F; Mazzanti CM; Bertacca G; Elisei R; Coscio GD; Pinchera A; Bevilacqua G
    Thyroid; 2009 Aug; 19(8):837-42. PubMed ID: 19534623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilities of
    Guan H; Toraldo G; Cerda S; Godley FA; Rao SR; McAneny D; Doherty G; Braverman L; Lee SL
    Thyroid; 2020 Apr; 30(4):536-547. PubMed ID: 31996097
    [No Abstract]   [Full Text] [Related]  

  • 8. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The variable phenotype and low-risk nature of RAS-positive thyroid nodules.
    Medici M; Kwong N; Angell TE; Marqusee E; Kim MI; Frates MC; Benson CB; Cibas ES; Barletta JA; Krane JF; Ruan DT; Cho NL; Gawande AA; Moore FD; Alexander EK
    BMC Med; 2015 Aug; 13():184. PubMed ID: 26253102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What to do with thyroid nodules showing benign cytology and BRAF(V600E) mutation? A study based on clinical and radiologic features using a highly sensitive analytic method.
    Kim SY; Kim EK; Kwak JY; Moon HJ; Yoon JH
    Surgery; 2015 Feb; 157(2):354-61. PubMed ID: 25616949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis.
    Nam SY; Han BK; Ko EY; Kang SS; Hahn SY; Hwang JY; Nam MY; Kim JW; Chung JH; Oh YL; Shin JH
    Thyroid; 2010 Mar; 20(3):273-9. PubMed ID: 20187782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of molecular testing in fine-needle aspiration biopsy samples: an experience in a Chinese population.
    Liu S; Gao A; Zhang B; Zhang Z; Zhao Y; Chen P; Ji M; Hou P; Shi B
    Exp Mol Pathol; 2014 Oct; 97(2):292-7. PubMed ID: 25111330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with "suspicious for malignant" cytology alone even when the nodules do not show suspicious US features.
    Seo JY; Kim EK; Kwak JY
    Endocrine; 2014 Sep; 47(1):283-9. PubMed ID: 24452872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
    Adeniran AJ; Hui P; Chhieng DC; Prasad ML; Schofield K; Theoharis C
    Acta Cytol; 2011; 55(6):570-5. PubMed ID: 22156468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discriminating Interpatient Variabilities of RAS Gene Variants for Precision Detection of Thyroid Cancer.
    Fu G; Chazen RS; MacMillan C; Witterick IJ
    JAMA Netw Open; 2024 May; 7(5):e2411919. PubMed ID: 38758552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular analysis of residual ThinPrep material from thyroid FNAs increases diagnostic sensitivity.
    Krane JF; Cibas ES; Alexander EK; Paschke R; Eszlinger M
    Cancer Cytopathol; 2015 Jun; 123(6):356-61. PubMed ID: 25926393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomorphologic features in thyroid nodules read as "suspicious for malignancy" on cytology may predict thyroid cancers with the BRAF mutation.
    Kwon HJ; Kim EK; Kwak JY
    Pathol Res Pract; 2015 Sep; 211(9):671-6. PubMed ID: 26187369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of
    Chen X; Zhou Q; Wang F; Zhang F; Du H; Zhang Q; Wu W; Gong X
    AJNR Am J Neuroradiol; 2018 Dec; 39(12):2360-2365. PubMed ID: 30498021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules.
    Kim SK; Kim DL; Han HS; Kim WS; Kim SJ; Moon WJ; Oh SY; Hwang TS
    Diagn Mol Pathol; 2008 Jun; 17(2):118-25. PubMed ID: 18382358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.
    Halászlaki C; Tóbiás B; Balla B; Kósa JP; Horányi J; Bölöny E; Nagy Z; Speer G; Járay B; Székely E; Istók R; Székely T; Putz Z; Dank M; Lakatos P; Takács I
    Endocr Pract; 2016 Sep; 22(9):1081-7. PubMed ID: 27214302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.